These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 32061907)

  • 1. Established and emerging factors affecting the progression of nonalcoholic fatty liver disease.
    Kechagias S; Nasr P; Blomdahl J; Ekstedt M
    Metabolism; 2020 Oct; 111S():154183. PubMed ID: 32061907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modifiers of Liver-Related Manifestation in the Course of NAFLD.
    Nasr P; Blomdahl J; Kechagias S; Ekstedt M
    Curr Pharm Des; 2020; 26(10):1062-1078. PubMed ID: 32156227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD).
    Johnston MP; Patel J; Byrne CD
    Curr Pharm Des; 2020; 26(10):1079-1092. PubMed ID: 32003662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
    Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
    World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
    Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
    Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Natural Course of Non-Alcoholic Fatty Liver Disease.
    Calzadilla Bertot L; Adams LA
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors in nonalcoholic fatty liver disease.
    Ko E; Yoon EL; Jun DW
    Clin Mol Hepatol; 2023 Feb; 29(Suppl):S79-S85. PubMed ID: 36517003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach.
    Grgurevic I; Podrug K; Mikolasevic I; Kukla M; Madir A; Tsochatzis EA
    Can J Gastroenterol Hepatol; 2020; 2020():9181368. PubMed ID: 32051820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic liver disease in diabetes - From mechanisms to clinical trials.
    Dewidar B; Kahl S; Pafili K; Roden M
    Metabolism; 2020 Oct; 111S():154299. PubMed ID: 32569680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease.
    Haas JT; Francque S; Staels B
    Annu Rev Physiol; 2016; 78():181-205. PubMed ID: 26667070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease: one entity, multiple impacts on liver health.
    Fierbinteanu-Braticevici C; Sinescu C; Moldoveanu A; Petrisor A; Diaconu S; Cretoiu D; Braticevici B
    Cell Biol Toxicol; 2017 Feb; 33(1):5-14. PubMed ID: 27680752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-alcoholic fatty liver disease: A review with clinical and pathological correlation.
    Chen YY; Yeh MM
    J Formos Med Assoc; 2021 Jan; 120(1 Pt 1):68-77. PubMed ID: 32654868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease in Asia: emerging perspectives.
    Seto WK; Yuen MF
    J Gastroenterol; 2017 Feb; 52(2):164-174. PubMed ID: 27637587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels.
    Akyuz U; Yesil A; Yilmaz Y
    Scand J Gastroenterol; 2015 Mar; 50(3):341-6. PubMed ID: 25540973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease.
    Crespo M; Lappe S; Feldstein AE; Alkhouri N
    Metabolism; 2016 Aug; 65(8):1161-71. PubMed ID: 26961580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
    Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
    Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
    Asrih M; Jornayvaz FR
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.